Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications.
What is Revance Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate RVNC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RVNC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RVNC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RVNC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RVNC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Revance Therapeutics's salary, the management and board of directors tenure and is there insider trading?
1.6yrs
Average management tenure
CEO
MarkFoley(54yo)
0.2yrs
Tenure
US$243,007
Compensation
Mr. Mark J. Foley serves as President and Chief Executive Officer at Revance Therapeutics, Inc. since October 14, 2019. He served as the Managing Director of RWI Ventures from 2004 to 2018. Mr. Foley joine ...
Management Age and Tenure
1.6yrs
Average Tenure
49yo
Average Age
Experienced Management: RVNC's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Age and Tenure
4.1yrs
Average Tenure
61.5yo
Average Age
Experienced Board: RVNC's board of directors are considered experienced (4.1 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.6%.
Management Team
Mark Foley (54yo)
President
Tenure: 0.2yrs
Compensation: US$243.01k
Abhay Joshi (56yo)
Chief Operating Officer
Tenure: 4yrs
Compensation: US$2.25m
Jeanie Herbert
Senior Director of Investor Relations & Corporate Communications
Tenure: 3yrs
Dustin Sjuts
Head of Commercial - Aesthetics & Therapeutics
Tenure: 1.1yrs
Roman Rubio (48yo)
Senior Vice President of Clinical Development
Tenure: 0yrs
Justin Ford
VP of Human Resources & Head of People
Tenure: 2.5yrs
Caryn McDowell (49yo)
Senior VP
Tenure: 1.6yrs
Compensation: US$2.80m
Toby Schilke (44yo)
CFO & Principal Accounting Officer
Tenure: 1.1yrs
Compensation: US$1.97m
Conor Gallagher
Head of Medical Affairs & Aesthetics
Tenure: 1.6yrs
Taryn Conway
Vice President of Marketing
Tenure: 0.7yrs
Board Members
Angus Russell (63yo)
Independent Chairman
Tenure: 5.8yrs
Compensation: US$269.98k
Phyllis Gardner (68yo)
Independent Director
Tenure: 13yrs
Compensation: US$233.01k
Bob Byrnes (74yo)
Independent Director
Tenure: 15.3yrs
Compensation: US$247.26k
Mark Foley (54yo)
President
Tenure: 0.2yrs
Compensation: US$243.01k
Jill Beraud (59yo)
Director
Tenure: 0.5yrs
Phil Vickers (59yo)
Independent Director
Tenure: 4.8yrs
Compensation: US$235.26k
Julian Gangolli (61yo)
Independent Director
Tenure: 3.4yrs
Compensation: US$230.51k
Chris Nolet (62yo)
Director
Tenure: 0.4yrs
Company Information
Revance Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications ...
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2019/12/13 00:45
End of Day Share Price
2019/12/12 00:00
Earnings
2019/09/30
Annual Earnings
2018/12/31
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.